losartan has been researched along with Coronary Disease in 23 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate effects of 6-month therapy with losartan in combination with indapamide on a clinical course, immunological, metabolic parameters, left ventricular function, exercise tolerance and quality of life in patients with coronary heart disease (CHD) associated with metabolic syndrome (MS)." | 9.14 | [Immunomodulating, metabolic and cardioprotective effects of AT1-angiotensin receptors blocker losartan in patients with coronary heart disease and type 2 diabetes mellitus]. ( Bolotskaia, LA; Derbeneva, NV; Frants, MV; Kuznetsova, AV; Lukinov, AV; Maianskaia, SD; Shilov, SN; Stepacheva, TA; Tepliakov, AT; Vdovina, TV, 2009) |
| " In patients with coronary disease, endothelium-bound XO activity as determined by ESR spectroscopy and endothelium-dependent vasodilation were analyzed before and after 4 weeks of treatment with the AT1-receptor blocker losartan, the XO inhibitor allopurinol, or placebo." | 7.74 | Angiotensin II induces endothelial xanthine oxidase activation: role for endothelial dysfunction in patients with coronary disease. ( Drexler, H; Fischer, D; Landmesser, U; Manes, C; Mueller, M; Preuss, C; Sorrentino, S; Spiekermann, S, 2007) |
| "The purpose of the present study was to evaluate the effects of losartan and the combination of losartan and L-arginine on endothelial function and hemodynamic variables in patients with heart failure (HF)." | 7.73 | Effects of losartan + L-arginine on nitric oxide production, endothelial cell function, and hemodynamic variables in patients with heart failure secondary to coronary heart disease. ( Bykhovsy, E; Chernihovsky, T; Keren, G; Koifman, B; Megidish, R; Topilski, I; Zelmanovich, L, 2006) |
| "Only quinapril was associated with significant improvement in FMD, and this response is related to the presence of the insertion allele of the ACE genotype." | 6.69 | Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study) ( Anderson, TJ; Charbonneau, F; Elstein, E; Haber, H, 2000) |
| "To evaluate effects of 6-month therapy with losartan in combination with indapamide on a clinical course, immunological, metabolic parameters, left ventricular function, exercise tolerance and quality of life in patients with coronary heart disease (CHD) associated with metabolic syndrome (MS)." | 5.14 | [Immunomodulating, metabolic and cardioprotective effects of AT1-angiotensin receptors blocker losartan in patients with coronary heart disease and type 2 diabetes mellitus]. ( Bolotskaia, LA; Derbeneva, NV; Frants, MV; Kuznetsova, AV; Lukinov, AV; Maianskaia, SD; Shilov, SN; Stepacheva, TA; Tepliakov, AT; Vdovina, TV, 2009) |
| " The following issues are reported in detail: (1) significance of statins, inhibition of platelet aggregation and vitamins in primary and secondary prevention of cardiovascular disease, (2) comparison of the angiotensin receptor blocker losartan and the beta-blocker atenolol in hypertension (LIFE study), (3) magnetic resonance angiography for the detection of coronary stenoses, (4) advantages and disadvantages of operative and interventional coronary revascularization considering elderly patients and sirolimus-eluting stents, and (5) efficacy of glycoprotein IIb/IIIa inhibition and low molecular weight heparin in acute myocardial infarction." | 4.82 | [From risk factors to symptomatic coronary artery disease. Update cardiology 2001/2002--part I]. ( Böhm, M; Fries, R, 2003) |
| "Through investigating the effect of the angiotensin receptor blocker (ARB) losartan on the number of endothelial progenitor cells (EPCs) and blood flow-mediated endothelium-dependent function (FMD) in the peripheral blood of patients with coronary heart disease (CHD), we found that FMD was improved and the number of circulating EPCs increased in the ARB treatment group (P <0." | 3.79 | Effects of losartan on the mobilization of endothelial progenitor cells and improvement of endothelial function. ( Chen, W; Chen, Y; Jin, Q; Li, X; Tan, H; Wei, X; Yang, Y; Zhang, H, 2013) |
| " In patients with coronary disease, endothelium-bound XO activity as determined by ESR spectroscopy and endothelium-dependent vasodilation were analyzed before and after 4 weeks of treatment with the AT1-receptor blocker losartan, the XO inhibitor allopurinol, or placebo." | 3.74 | Angiotensin II induces endothelial xanthine oxidase activation: role for endothelial dysfunction in patients with coronary disease. ( Drexler, H; Fischer, D; Landmesser, U; Manes, C; Mueller, M; Preuss, C; Sorrentino, S; Spiekermann, S, 2007) |
| "The purpose of the present study was to evaluate the effects of losartan and the combination of losartan and L-arginine on endothelial function and hemodynamic variables in patients with heart failure (HF)." | 3.73 | Effects of losartan + L-arginine on nitric oxide production, endothelial cell function, and hemodynamic variables in patients with heart failure secondary to coronary heart disease. ( Bykhovsy, E; Chernihovsky, T; Keren, G; Koifman, B; Megidish, R; Topilski, I; Zelmanovich, L, 2006) |
| " We hypothesized that both ACE inhibitor (ACEI) and angiotensin II type 1 receptor antagonist (AT(1)-A) increase bioavailability of nitric oxide (NO) by reducing oxidative stress in the vessel wall, possibly by increasing EC-SOD activity." | 2.70 | Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. ( Ahlersmann, D; Christoph, A; Drexler, H; Hornig, B; Kohler, C; Landmesser, U; Spiekermann, S; Tatge, H, 2001) |
| "Only quinapril was associated with significant improvement in FMD, and this response is related to the presence of the insertion allele of the ACE genotype." | 2.69 | Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study) ( Anderson, TJ; Charbonneau, F; Elstein, E; Haber, H, 2000) |
| "Hypertension is a major influence on the development of LVH." | 2.43 | Ventricular hypertrophy and hypertension: prognostic elements and implications for management. ( Devereux, RB; Krauser, DG, 2006) |
| "Losartan is a non-peptidic inhibitor of AT1 receptors." | 2.41 | Angiotensin II AT(1) receptor antagonists and platelet activation. ( Casado, S; Gómez, J; Jiménez, A; Lopez-Bloya, A; López-Farré, A; Montón, M; Núñez, A; Rico, L; Sánchez de Miguel, L, 2001) |
| "Treatment with captopril (10(-6) mol/l) increased the neointimal proliferation by approximately 200% after angioplasty." | 1.30 | Angiotensin II receptor antagonists prevent neointimal proliferation in a porcine coronary artery organ culture model. ( Cheung, PK; Saward, L; Wilson, DP; Zahradka, P, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (13.04) | 18.2507 |
| 2000's | 18 (78.26) | 29.6817 |
| 2010's | 2 (8.70) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tan, H | 1 |
| Li, X | 1 |
| Chen, W | 1 |
| Chen, Y | 1 |
| Wei, X | 1 |
| Yang, Y | 1 |
| Zhang, H | 1 |
| Jin, Q | 1 |
| Vatseba, MO | 1 |
| Krikken, JA | 1 |
| Waanders, F | 1 |
| Dallinga-Thie, GM | 1 |
| Dikkeschei, LD | 1 |
| Vogt, L | 1 |
| Navis, GJ | 1 |
| Dullaart, RP | 1 |
| Tepliakov, AT | 1 |
| Maianskaia, SD | 1 |
| Bolotskaia, LA | 1 |
| Vdovina, TV | 1 |
| Stepacheva, TA | 1 |
| Kuznetsova, AV | 1 |
| Lukinov, AV | 1 |
| Derbeneva, NV | 1 |
| Frants, MV | 1 |
| Shilov, SN | 1 |
| Richter, MH | 1 |
| Richter, H | 2 |
| Barten, M | 1 |
| Schramm, D | 2 |
| Gummert, J | 1 |
| Mohr, FW | 1 |
| Skupin, M | 2 |
| Olbrich, HG | 2 |
| Schmieder, RE | 1 |
| Schneider, MP | 1 |
| Hornig, B | 2 |
| Fries, R | 1 |
| Böhm, M | 1 |
| Bramlage, P | 1 |
| Wittchen, HU | 1 |
| Pittrow, D | 1 |
| Dikow, R | 1 |
| Kirch, W | 1 |
| Lehnert, H | 1 |
| Ritz, E | 1 |
| Tomiyama, H | 1 |
| Takata, Y | 1 |
| Yamashina, A | 1 |
| Iwai, K | 1 |
| Morimoto, S | 1 |
| Matsumoto, M | 1 |
| Baumgart, P | 1 |
| Cheung, BM | 1 |
| Krauser, DG | 1 |
| Devereux, RB | 1 |
| Koifman, B | 1 |
| Topilski, I | 1 |
| Megidish, R | 1 |
| Zelmanovich, L | 1 |
| Chernihovsky, T | 1 |
| Bykhovsy, E | 1 |
| Keren, G | 1 |
| Landmesser, U | 2 |
| Spiekermann, S | 2 |
| Preuss, C | 1 |
| Sorrentino, S | 1 |
| Fischer, D | 1 |
| Manes, C | 1 |
| Mueller, M | 1 |
| Drexler, H | 2 |
| Krasnikova, TL | 1 |
| Wilson, DP | 1 |
| Saward, L | 1 |
| Zahradka, P | 1 |
| Cheung, PK | 1 |
| Alderman, M | 1 |
| Anderson, TJ | 1 |
| Elstein, E | 1 |
| Haber, H | 1 |
| Charbonneau, F | 1 |
| Richter, M | 1 |
| Grabs, R | 1 |
| Kohler, C | 1 |
| Ahlersmann, D | 1 |
| Christoph, A | 1 |
| Tatge, H | 1 |
| López-Farré, A | 1 |
| Sánchez de Miguel, L | 1 |
| Montón, M | 1 |
| Jiménez, A | 1 |
| Lopez-Bloya, A | 1 |
| Gómez, J | 1 |
| Núñez, A | 1 |
| Rico, L | 1 |
| Casado, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Trial of the Effect of Perindopril on HFSR Incidence and Severity in Patients Receiving Regorafenib With Refractory Metastatic Colorectal Carcinoma (mCRC)[NCT02651415] | Phase 2 | 12 participants (Actual) | Interventional | 2016-08-31 | Completed | ||
| Impact of Spironolactone on Endothelial Function in Patients With Single Ventricle Heart[NCT00211081] | 12 participants (Actual) | Interventional | 2004-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Median time course for participants to develop worst grade 3 HFSR toxicity is defined as the time (days) from start date of study drug to date of first documented grade 3 HFSR toxicity and will be calculated only for patients who had a HFSR toxicity grade 3. (NCT02651415)
Timeframe: p to Safety Follow-Up Visit (30 days +/- 7 days after permanently stopping study treatment)
| Intervention | days (Median) |
|---|---|
| Single Arm Trial | 12 |
Median time (in months) to PFS. PFS is defined as the time from start date of study drugs to the date of first documented disease progression (radiological or clinical) or death due to any cause, if death occurs before progression is documented. PFS will be evaluated based on RECIST v1.1 criteria, 20% progression or any new lesion. (NCT02651415)
Timeframe: From start date of study drugs to the date of first documented disease progression or death due to any cause.
| Intervention | Months (Median) |
|---|---|
| Single Arm Trial | 2.60 |
"The trial will measure the toxicities of HFSR in participants receiving both perindopril and regorafenib using the CTCAE v4.03 criteria.~The toxicity of HFSR will be expressed based on the number of participants in the study (N=10) who are experiencing HFSR of all grades." (NCT02651415)
Timeframe: Up to Safety Follow-Up Visit (30 days +/- 7 days after permanently stopping study treatment)
| Intervention | Participants (Count of Participants) |
|---|---|
| Single Arm Trial | 7 |
The number of participants that experienced an HFSR of grade 3 or above as assessed by CTCAE v4.03 criteria when treated with a combination of regorafenib and perindopril. (NCT02651415)
Timeframe: Up to Safety Follow-Up Visit (30 days +/- 7 days after permanently stopping study treatment)
| Intervention | Participants (Count of Participants) |
|---|---|
| Single Arm Trial | 5 |
All grades of adverse events (including HFSR) will be evaluated using CTCAE v4.03, at baseline and at D1 of each cycle while they are on the study drug and during the 30-day follow-up period (Post therapy). (NCT02651415)
Timeframe: At baseline and at D1 of each cycle while on the study drug and during the 30-day follow-up period
| Intervention | participants (Number) |
|---|---|
| Single Arm Trial | 10 |
All grades of hypertension will be evaluated using CTCAE v4.03, weekly for the first six weeks while they are on the study drug, then every second week and during the 30-day follow-up period (Post therapy). (NCT02651415)
Timeframe: Weekly for the first six weeks while on the study drug, then every second week and during the 30-day follow-up period
| Intervention | Participants (Count of Participants) |
|---|---|
| Single Arm Trial | 6 |
Flow-mediated dilation of the brachial artery will be measured using high-resolution ultrasound. Arterial diameter will be measured above the small cavity in the elbow joint from ultrasound images at rest in response to an increase in blood flow to the area. (NCT00211081)
Timeframe: Baseline, Post-Intervention (4 Weeks)
| Intervention | Percentage of brachial artery diameter (Mean) |
|---|---|
| Spironolactone | 5.5 |
The normal reference range for C-reactive protein is as follows: CRP: 0-10mg/L (NCT00211081)
Timeframe: Baseline, Post-Intervention (4 Weeks)
| Intervention | mg/L (Median) | |
|---|---|---|
| Baseline | 4 Week Follow Up | |
| Spironolactone | 1.10 | 1.10 |
The normal result for IL1b is <3.9 pg/mL. (NCT00211081)
Timeframe: Baseline, Post-Intervention (4 Weeks)
| Intervention | pg/mL (Median) | |
|---|---|---|
| Baseline | 4 Week Follow Up | |
| Spironolactone | .38 | .23 |
The normal result for IL-10 for Interleukin 10 is < 18pg/ml. (NCT00211081)
Timeframe: Baseline, Post-Intervention (4 Weeks)
| Intervention | 18pg/ml (Median) | |
|---|---|---|
| Baseline | 4 Week Follow Up | |
| Spironolactone | .26 | .13 |
The normal result for IL-6 for Interleukin 6 is < 5pg/ml. (NCT00211081)
Timeframe: Baseline, Post-Intervention (4 Weeks)
| Intervention | pg/ml (Median) | |
|---|---|---|
| Baseline | 4 Week Follow Up | |
| Spironolactone | 1.96 | 1.54 |
The normal result for TNF-a is <5.6 pg/mL. (NCT00211081)
Timeframe: Baseline, Post-Intervention (4 Weeks)
| Intervention | pg/mL (Median) | |
|---|---|---|
| Baseline | 4 Week Follow Up | |
| Spironolactone | 2.20 | 2.42 |
9 reviews available for losartan and Coronary Disease
| Article | Year |
|---|---|
Vitamins, antioxidants and endothelial function in coronary artery disease.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antioxidants; Ascorbic A | 2002 |
[From risk factors to symptomatic coronary artery disease. Update cardiology 2001/2002--part I].
Topics: Abciximab; Adult; Age Factors; Aged; Aged, 80 and over; Angina, Unstable; Antibodies, Monoclonal; An | 2003 |
[Management of hypertensive patients with cardiovascular damage].
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2004 |
[Treatment of hypertension in elderly patients with coronary heart disease].
Topics: Adrenergic beta-Antagonists; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin- | 2005 |
Therapeutic potential of angiotensin receptor blockers in hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; C | 2006 |
Ventricular hypertrophy and hypertension: prognostic elements and implications for management.
Topics: Adrenergic Antagonists; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Convert | 2006 |
[Losartan, an angiotensin II receptor blocker: a new trend in cardiovascular chemotherapy].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compoun | 1996 |
Uric acid in hypertension and cardiovascular disease.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biomarkers; Blood Pressure; Coronary Dise | 1999 |
Angiotensin II AT(1) receptor antagonists and platelet activation.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Angiotensin Receptor Antagonists | 2001 |
4 trials available for losartan and Coronary Disease
| Article | Year |
|---|---|
Antiproteinuric therapy decreases LDL-cholesterol as well as HDL-cholesterol in non-diabetic proteinuric patients: relationships with cholesteryl ester transfer protein mass and adiponectin.
Topics: Adiponectin; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Cholesterol Ester Transfer Protei | 2009 |
[Immunomodulating, metabolic and cardioprotective effects of AT1-angiotensin receptors blocker losartan in patients with coronary heart disease and type 2 diabetes mellitus].
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cardiotonic Agents; C | 2009 |
Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study)
Topics: Aged; Amlodipine; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Blood Flow Velocity; Cal | 2000 |
Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study)
Topics: Aged; Amlodipine; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Blood Flow Velocity; Cal | 2000 |
Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study)
Topics: Aged; Amlodipine; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Blood Flow Velocity; Cal | 2000 |
Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study)
Topics: Aged; Amlodipine; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Blood Flow Velocity; Cal | 2000 |
Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antioxidants; Ascorbic A | 2001 |
10 other studies available for losartan and Coronary Disease
| Article | Year |
|---|---|
Effects of losartan on the mobilization of endothelial progenitor cells and improvement of endothelial function.
Topics: Aged; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Brachial Artery; China; Coronar | 2013 |
[Endothelial dysfunction as a marker of vascular aging syndrome on the background of hypertension, coronary heart disease, gout and obesity].
Topics: Antihypertensive Agents; Blood Flow Velocity; Blood Pressure; Cardiovascular Agents; Carotid Arterie | 2013 |
Angiotensin II type 1 receptor blockade after cardiac transplantation reduced the incidence and severity of transplant vasculopathy in an animal-based study.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Coronary Diseas | 2002 |
[Left ventricular hypertrophy. Recent aspects of diagnosis and therapy].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 2002 |
[Microalbuminuria is an early marker for increased morbidity and mortality].
Topics: Albuminuria; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biom | 2003 |
[Antihypertensive therapy: risk stratification in diabetes and cardiac diseases].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2006 |
Effects of losartan + L-arginine on nitric oxide production, endothelial cell function, and hemodynamic variables in patients with heart failure secondary to coronary heart disease.
Topics: Administration, Oral; Aged; Angiotensin II Type 1 Receptor Blockers; Arginine; Brachial Artery; Coro | 2006 |
Angiotensin II induces endothelial xanthine oxidase activation: role for endothelial dysfunction in patients with coronary disease.
Topics: Aged; Allopurinol; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cattle; Cells, | 2007 |
Angiotensin II receptor antagonists prevent neointimal proliferation in a porcine coronary artery organ culture model.
Topics: Analysis of Variance; Angioplasty, Balloon, Coronary; Angiotensin II; Angiotensin Receptor Antagonis | 1999 |
New approach in the therapy of chronic rejection? ACE- and AT1-blocker reduce the development of chronic rejection after cardiac transplantation in a rat model.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Coronary Disease; Coronary Vessel | 2000 |